Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid)

Mortality 16 to 60 weeks · people with asthma

Subcutaneous omalizumab + steroid showed no clear difference in mortality 16 to 60 weeks compared with placebo + steroid (stable steroid) (low certainty).

1 finding from 1 review

Omalizumab for asthma in adults and children 2014 · Cochrane Headline outcomes only
OR 0.19 [0.02, 1.67]
9 studies · 4245 participants
Low